These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23153066)

  • 1. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
    Sukowati CH; Rosso N; Pascut D; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
    BMC Gastroenterol; 2012 Nov; 12():160. PubMed ID: 23153066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
    Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
    Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study.
    Sukowati CH; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
    PLoS One; 2013; 8(10):e76830. PubMed ID: 24116172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
    Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
    Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
    Huang WC; Hsieh YL; Hung CM; Chien PH; Chien YF; Chen LC; Tu CY; Chen CH; Hsu SC; Lin YM; Chen YJ
    PLoS One; 2013; 8(12):e83627. PubMed ID: 24391798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
    Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
    Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
    Jia Q; Zhang X; Deng T; Gao J
    Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
    Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
    Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
    Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
    J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCG2 expression, function, and promoter methylation in human multiple myeloma.
    Turner JG; Gump JL; Zhang C; Cook JM; Marchion D; Hazlehurst L; Munster P; Schell MJ; Dalton WS; Sullivan DM
    Blood; 2006 Dec; 108(12):3881-9. PubMed ID: 16917002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
    Takahata T; Ookawa K; Suto K; Tanaka M; Yano H; Nakashima O; Kojiro M; Tamura Y; Tateishi T; Sakata Y; Fukuda S
    Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):399-407. PubMed ID: 18248513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver.
    Chisaki I; Kobayashi M; Itagaki S; Hirano T; Iseki K
    Biochim Biophys Acta; 2009 Nov; 1788(11):2396-403. PubMed ID: 19728987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.
    Hu C; Li H; Li J; Zhu Z; Yin S; Hao X; Yao M; Zheng S; Gu J
    Carcinogenesis; 2008 Dec; 29(12):2289-97. PubMed ID: 18820285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells.
    Yin W; Xiang D; Wang T; Zhang Y; Pham CV; Zhou S; Jiang G; Hou Y; Zhu Y; Han Y; Qiao L; Tran PH; Duan W
    Sci Rep; 2021 May; 11(1):10791. PubMed ID: 34031441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs.
    Hashimoto N; Tsunedomi R; Yoshimura K; Watanabe Y; Hazama S; Oka M
    BMC Cancer; 2014 Sep; 14():722. PubMed ID: 25260650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.
    Pang E; Hu Y; Chan KY; Lai PB; Squire JA; Macgregor PF; Beheshti B; Albert M; Leung TW; Wong N
    Lab Invest; 2005 May; 85(5):664-74. PubMed ID: 15765123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation.
    Liu L; Chen X; Xie S; Zhang C; Qiu Z; Zhu F
    Hepatology; 2012 Nov; 56(5):1760-9. PubMed ID: 22576474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.